8-K: Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics announced its third quarter 2024 financial results, highlighting a partnership with Enable Injections and progress on its lead candidate SER-252.

Summary

• Serina Therapeutics reported its financial results for the third quarter ended September 30, 2024.
• The company's revenue was primarily from NIH grants, totaling $14 thousand for the quarter, down from $29 thousand in the same period last year.
• Operating expenses increased significantly to $5.3 million, compared to $1.5 million in the third quarter of 2023.
• Research and development expenses rose to $2.4 million, up from $0.6 million, due to increased headcount, patent maintenance, and research services.
• General and administrative expenses increased to $2.9 million from $0.9 million, driven by stock-based compensation, consulting, and severance costs.
• Other income, net, increased to $6.7 million, primarily due to a gain in the fair value of merger warrants.
• Net income for the quarter was $1.4 million, or $0.16 per share basic and $0.13 per share diluted, compared to $1.8 million, or $0.80 per share basic and $0.23 per share diluted, in 2023.
• Cash, cash equivalents, and restricted cash totaled $3.2 million as of September 30, 2024.
• The company has concerns about its ability to continue as a going concern, as current cash and expected proceeds from warrant exercises may not be sufficient to meet operating needs for the next twelve months.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern warning and increased operating expenses, overshadowing positive developments like the Enable Injections partnership. The decrease in net income per share and low cash position contribute to a negative sentiment.

Positives

• The partnership with Enable Injections could improve patient comfort and convenience for Parkinson's disease treatment.
• The company is advancing its lead candidate, SER-252, towards clinical testing in 2025.
• The POZ platform has potential for use across a broad range of payloads and indications.
• The company has a non-exclusive license agreement with Pfizer for its POZ polymer technology.
• The company reported a net income of $1.4 million for the quarter.

Negatives

• Operating expenses have significantly increased year-over-year.
• The company's cash position is low at $3.2 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• Grant revenue decreased from $29 thousand to $14 thousand year-over-year.
• Net income per share decreased from $0.80 to $0.16 basic and $0.23 to $0.13 diluted year-over-year.

Risks

• The company's current cash and expected warrant proceeds may not be sufficient to meet operating needs for the next twelve months.
• There are uncertainties inherent in research and development, including clinical trial outcomes and regulatory approvals.
• The company faces competitive developments in the biotechnology industry.
• The company's financial statements are subject to differing interpretations and assessments by regulatory authorities.
• The company's ability to continue as a going concern is in doubt.

Future Outlook

The company plans to advance SER-252 to clinical testing in 2025 and intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements. The company also expects to receive approximately $10 million from Juvenescence through the exercise of warrants.

Management Comments

• The company believes that its cash and cash equivalents of $3.2 million as of September 30, 2024 with the approximately $10 million of cash proceeds expected to be received from Juvenescence through the exercise of Juvenescences remaining Post-Merger Warrants as provided in a Side Letter would not be sufficient to satisfy the Companys anticipated operating and other funding requirements for the twelve months following the filing of the Companys Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2024.

Industry Context

The collaboration with Enable Injections reflects a trend in the pharmaceutical industry towards patient-centric drug delivery solutions. The focus on continuous dopaminergic stimulation for Parkinson's disease aligns with ongoing efforts to improve treatment outcomes for this condition. The company's POZ platform is also part of a broader trend in drug delivery technology.

Comparison to Industry Standards

• Serina's R&D spending increase is typical for a clinical-stage biotech company advancing a lead candidate, but the magnitude of the increase is significant.
• The company's cash position of $3.2 million is low compared to other clinical-stage biotech companies, raising concerns about its ability to fund operations.
• The going concern warning is a significant concern and is not typical for companies with a clear path to funding.
• The partnership with Enable Injections is a positive development, but the company's financial situation is a major challenge.
• The company's net income of $1.4 million is not a typical result for a clinical stage biotech company, and is largely due to non-cash gains from warrant revaluations.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern warning and low cash position.
• Employees may be concerned about the company's financial stability.
• Customers and partners may be concerned about the company's ability to continue operations.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• Serina plans to advance SER-252 to clinical testing in 2025.
• The company intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

Key Dates

Keywords

Serina Therapeutics, SER-252, POZ Platform, Parkinson's disease, biotechnology, clinical-stage, drug delivery, financial results, Enable Injections, warrants